Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
BIOA
BioAge Labs
$4.28
+0.9%
$0.00
$2.88
$26.62
$153.44MN/A296,430 shs100,790 shs
Cybin Inc. stock logo
CYBN
Cybin
$7.98
+8.1%
$7.62
$4.81
$13.88
$182.81M0.69280,375 shs442,098 shs
Neos Therapeutics, Inc. stock logo
NEOS
Neos Therapeutics
$1.15
$1.06
$0.45
$1.68
$57.22M1.57.44 million shs15.01 million shs
Neoleukin Therapeutics, Inc. stock logo
NLTX
Neoleukin Therapeutics
$20.09
+1.7%
$17.70
$2.03
$14.36
$188.81M1.1150,104 shs75,550 shs
 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
BIOA
BioAge Labs
0.00%+427,999,900.00%+427,999,900.00%+427,999,900.00%+427,999,900.00%
Cybin Inc. stock logo
CYBN
Cybin
0.00%-2.15%-9.58%+40.16%+2,061.25%
Neos Therapeutics, Inc. stock logo
NEOS
Neos Therapeutics
0.00%0.00%0.00%0.00%0.00%
Neoleukin Therapeutics, Inc. stock logo
NLTX
Neoleukin Therapeutics
0.00%+24.32%-7.29%+128.56%-44.16%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
BIOA
BioAge Labs
N/AN/AN/AN/AN/AN/AN/AN/A
Cybin Inc. stock logo
CYBN
Cybin
3.1208 of 5 stars
3.60.00.00.03.80.81.3
Neos Therapeutics, Inc. stock logo
NEOS
Neos Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
Neoleukin Therapeutics, Inc. stock logo
NLTX
Neoleukin Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
BIOA
BioAge Labs
0.00
N/AN/AN/A
Cybin Inc. stock logo
CYBN
Cybin
3.25
Buy$86.00978.37% Upside
Neos Therapeutics, Inc. stock logo
NEOS
Neos Therapeutics
0.00
N/AN/AN/A
Neoleukin Therapeutics, Inc. stock logo
NLTX
Neoleukin Therapeutics
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest NEOS, CYBN, BIOA, and NLTX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/13/2025
Cybin Inc. stock logo
CYBN
Cybin
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
(Data available from 7/6/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
BIOA
BioAge Labs
N/AN/AN/AN/A$9.01 per shareN/A
Cybin Inc. stock logo
CYBN
Cybin
N/AN/AN/AN/A$10.83 per shareN/A
Neos Therapeutics, Inc. stock logo
NEOS
Neos Therapeutics
$64.65M0.89N/AN/A($0.12) per share-9.58
Neoleukin Therapeutics, Inc. stock logo
NLTX
Neoleukin Therapeutics
N/AN/AN/AN/A$11.08 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
BIOA
BioAge Labs
-$71.11MN/A0.00N/AN/AN/AN/AN/A
Cybin Inc. stock logo
CYBN
Cybin
-$57.88M-$3.88N/AN/AN/AN/A-37.58%-36.59%N/A
Neos Therapeutics, Inc. stock logo
NEOS
Neos Therapeutics
-$16.90M-$0.34N/AN/AN/A-38.35%N/A-28.46%N/A
Neoleukin Therapeutics, Inc. stock logo
NLTX
Neoleukin Therapeutics
-$57.56M-$3.11N/AN/AN/A-37.22%-30.91%N/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
BIOA
BioAge Labs
N/AN/AN/AN/AN/A
Cybin Inc. stock logo
CYBN
Cybin
N/AN/AN/AN/AN/A
Neos Therapeutics, Inc. stock logo
NEOS
Neos Therapeutics
N/AN/AN/AN/AN/A
Neoleukin Therapeutics, Inc. stock logo
NLTX
Neoleukin Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
BIOA
BioAge Labs
N/A
13.68
13.68
Cybin Inc. stock logo
CYBN
Cybin
N/A
24.24
24.24
Neos Therapeutics, Inc. stock logo
NEOS
Neos Therapeutics
N/A
0.66
0.53
Neoleukin Therapeutics, Inc. stock logo
NLTX
Neoleukin Therapeutics
N/A
15.33
15.33

Institutional Ownership

CompanyInstitutional Ownership
BIOA
BioAge Labs
N/A
Cybin Inc. stock logo
CYBN
Cybin
17.94%
Neos Therapeutics, Inc. stock logo
NEOS
Neos Therapeutics
33.13%
Neoleukin Therapeutics, Inc. stock logo
NLTX
Neoleukin Therapeutics
52.37%

Insider Ownership

CompanyInsider Ownership
BIOA
BioAge Labs
20.82%
Cybin Inc. stock logo
CYBN
Cybin
15.00%
Neos Therapeutics, Inc. stock logo
NEOS
Neos Therapeutics
3.80%
Neoleukin Therapeutics, Inc. stock logo
NLTX
Neoleukin Therapeutics
1.58%
CompanyEmployeesShares OutstandingFree FloatOptionable
BIOA
BioAge Labs
N/A35.85 million28.39 millionN/A
Cybin Inc. stock logo
CYBN
Cybin
5023.02 million17.96 millionNot Optionable
Neos Therapeutics, Inc. stock logo
NEOS
Neos Therapeutics
21349.76 millionN/AOptionable
Neoleukin Therapeutics, Inc. stock logo
NLTX
Neoleukin Therapeutics
909.40 million9.25 millionNo Data

Recent News About These Companies

(NGNE) Proactive Strategies
Neurogene concludes merger deal with Neoleukin Therapeutics
Neoleukin Therapeutics Announces 1-for-4 Reverse Stock Split
Pre-market Movers: ORTX, CMBM, GROM, RSVR, FEMY…
Neoleukin Therapeutics Announces 1-for-5 Reverse Stock Split
Neoleukin Therapeutics Recent Insider Activity

New MarketBeat Followers Over Time

Media Sentiment Over Time

BioAge Labs NASDAQ:BIOA

$4.28 +0.04 (+0.94%)
As of 07/3/2025 01:00 PM Eastern

We are a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases, such as obesity, by targeting the biology of human aging. Our technology platform and differentiated human datasets enable us to identify promising targets based on insights into molecular changes that drive aging. Our primary focus is metabolic disease, one of the greatest global healthcare challenges. Azelaprag, our lead product candidate, is an orally available small molecule that has been well-tolerated in 265 individuals across eight Phase 1 clinical trials. In preclinical obesity models, azelaprag demonstrated the ability to more than double the weight loss induced by a glucagon-like-peptide-1 receptor (GLP-1R) agonist while also restoring healthy body composition and improving muscle function. These preclinical results are supported by our Phase 1b clinical trial in older adults on bed rest where we observed decreased muscle atrophy, preservation of muscle quality and improved metabolism in subjects treated with azelaprag over a 10-day period. We plan to assess azelaprag’s potential to drive significant improvements in weight loss when combined with a GLP-1R agonist in two Phase 2 clinical trials. While the results of these preclinical studies and early clinical trials have demonstrated the potential use of azelaprag for the treatment of metabolic disease, they may not be predictive of the results of later-stage clinical trials. The ongoing STRIDES clinical trial will assess azelaprag in combination with tirzepatide, marketed as Zepbound® by Eli Lilly and Company (Lilly), with topline results anticipated in the third quarter of 2025. The second Phase 2 clinical trial will assess azelaprag in combination with semaglutide, marketed as Wegovy® by Novo Nordisk, with initiation expected in the first half of 2025 and topline results expected in the second half of 2026. We believe these trials will directly support our ultimate therapeutic goal of developing an all-oral combination product for obesity. We also intend to initiate an insulin sensitivity proof-of-concept trial of azelaprag monotherapy in the first half of 2025 to support potential indication expansion. We expect to report topline results from this proof-of-concept trial in the second half of 2025. We are also developing orally available small molecule brain-penetrant NLRP3 inhibitors for the treatment of diseases driven by neuroinflammation. We anticipate submitting an Investigational New Drug application (IND) for an NLRP3 inhibitor in the second half of 2025 and, if cleared, initiating a Phase 1 clinical trial in the first half of 2026. Our approach: Targeting human aging biology to treat chronic metabolic diseases The burden of many serious and chronic diseases—including cardiovascular disease and diabetes—increases with age. However, there is substantial natural variation in the human population, resulting in a broad range of aging trajectories and outcomes, with some people experiencing much longer lifespans as well as delayed disease onset. We created our company to identify biological pathways associated with longer, healthier human lifespans and to develop pharmaceutical products that can modulate these pathways with the intent to prevent and reverse specific diseases, focusing on metabolic diseases. --- Our approach starts with human data. We examine the impact of the molecular changes that happen naturally as people age and study how these changes drive both functional decline (e.g., loss of muscle strength) and disease risk (e.g., obesity, insulin resistance, dyslipidemia, hypertension). To develop new insights into the biological drivers of aging, we have generated proprietary longitudinal human datasets based on exclusive access to a unique resource: serial biobanked human samples coupled with health records and functional measurements collected for up to 50 years, capturing individual aging trajectories measured over several decades. We analyze these samples using state-of-the-artmolecular profiling technologies, measuring thousands of biologically relevant molecules, and then apply computational tools to the resulting data to extract potential drivers of a long and healthy lifespan. --- We have selected chronic metabolic diseases as our primary focus within age related chronic diseases, given their high prevalence and resulting potential for impact on population health. Chronic metabolic diseases represent some of the largest addressable therapeutics markets. Through our approach, we expect to target outsized commercial opportunities, initially within the obesity and diabetes landscape. For instance, according to third-party estimates, the global market for GLP-1R agonists, including those used to treat diabetes, is expected to grow to $150 billion by 2031. We were incorporated under the laws of the State of Delaware on April 1, 2015, under the name BioAge Labs, Inc. Our principal executive offices are located at 1445A South 50th Street, Richmond, California.

Cybin stock logo

Cybin NYSE:CYBN

$7.98 +0.60 (+8.06%)
Closing price 07/3/2025 03:58 PM Eastern
Extended Trading
$7.96 -0.01 (-0.19%)
As of 07/3/2025 04:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Cybin Inc., a clinical-stage biopharmaceutical company, focuses on developing psychedelic-based therapeutics for patients with mental health conditions. The company's development pipeline includes CYB003, a deuterated psilocybin analog, which is in phase 1/2a clinical trial to treat major depressive disorder (MDD), as well as in preclinical trials for alcohol use disorder; CYB004, a deuterated dimethyltryptamine (DMT), which completed phase 2 clinical trial for treating generalized anxiety disorders; SPL028 injectable deuterated DMT completed phase 1 clinical intramuscular and intravenous trial; SPL026 completed phase 1, 1b, and 1/2a for MDD; and CYB005, a phenethylamine derivative, which in preclinical stage to treat neuroinflammation, as well as has a research pipeline of investigational psychedelic-based compounds. The company has research and collaboration agreement with TMS Neurohealth Centers Inc. for development of psychedelic compound-based therapeutics; Kernel for use of Kernel flow technology to measure neural activity; and Greenbook TMS to establish mental health centers. The company is headquartered in Toronto, Canada.

Neos Therapeutics stock logo

Neos Therapeutics NASDAQ:NEOS

Neos Therapeutics, Inc., a pharmaceutical company, develops, manufactures, and commercializes products for the treatment of attention deficit hyperactivity disorder (ADHD) using its drug delivery technology platform. Its products are extended-release (XR) medications in orally disintegrating tablets or liquid suspension dosage forms. The company manufactures and markets Adzenys XR-ODT amphetamine for the treatment of ADHD; Cotempla XR-ODT methylphenidate to treat ADHD; Adzenys ER amphetamine for the treatment of ADHD; and generic Tussionex, a hydrocodone and chlorpheniramine polistirex XR oral suspension for cough and upper respiratory symptoms of a cold. It also offers NT0502, a clinical-stage product candidate that has completed Phase I pilot pharmacokinetic trial for the treatment of neurological conditions associated with excessive salivation and drooling to reduce chronic sialorrhea in patients. The company was incorporated in 2009 and is headquartered in Grand Prairie, Texas.

Neoleukin Therapeutics stock logo

Neoleukin Therapeutics NASDAQ:NLTX

$20.09 +0.34 (+1.72%)
As of 07/3/2025

Neoleukin Therapeutics, Inc., a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology. The company's lead product candidate is NL-201, a de novo protein designed to mimic the therapeutic activity of the cytokines interleukin (IL)-2/IL-15 for the treatment of various types of cancer, including renal cell carcinoma and melanoma. The company was formerly known as Aquinox Pharmaceuticals, Inc. and changed its name to Neoleukin Therapeutics, Inc. in August 2019. Neoleukin Therapeutics, Inc. was founded in 2003 and is headquartered in Seattle, Washington.